Charles Fain Lehman, a Senior Fellow at the Manhattan Institute and Senior Editor of City Journal, has recently questioned the effectiveness of supervised consumption sites (SCSs) in mitigating the opioid crisis. In an opinion piece co-authored for The Washington Post on April 20, 2026, Lehman contended that these facilities, also known as harm reduction centers, "aren't stopping overdoses" at a population level and disrupt communities. His analysis suggests that despite claims of on-site overdose reversals, SCSs do not measurably reduce overall overdose deaths.
Lehman's argument, rooted in a report for the Foundation of Drug Policy Solutions, reviewed evidence indicating that SCSs have no discernible effect on nonfatal or fatal overdose rates. He highlighted studies from Barcelona and Vancouver, British Columbia, which found no reduction in nonfatal overdose rates among users, and Canadian studies that showed no impact on hospitalization or overdose death rates after SCS implementation. The piece also mentioned the federal "crack house statute" making it illegal to maintain a place for controlled substance use, citing a 2021 ruling against a Philadelphia SCS.
Conversely, a substantial body of peer-reviewed research supports the efficacy of supervised consumption sites in reducing various drug-related harms. Studies, particularly from Vancouver's Insite, North America's first SCS, have shown associations with lower overdose mortality, a 67% reduction in ambulance calls for overdoses, and decreased HIV infections among users within the immediate vicinity. Advocates emphasize that millions of drug use episodes have been supervised at SCSs without a single reported fatal overdose within the facilities.
However, the debate often centers on the distinction between on-site harm reduction and broader population-level impact. While SCSs demonstrably prevent overdoses within their walls, some analyses, including a March 2026 article in the National Post, suggest that the closure of certain sites in Canada did not lead to an increase in fatal overdoses. This highlights the complexity of attributing population-wide changes directly to SCS operations, especially when considering other factors like drug supply toxicity or access to treatment.
The ongoing discussion underscores a fundamental disagreement in drug policy: whether SCSs provide sufficient public health benefits to outweigh concerns about their broader community impact and legal standing. Policy decisions continue to navigate conflicting research findings and diverse stakeholder perspectives on the most effective strategies to combat the opioid epidemic.
